Covenant Asset Management’s AstraZeneca AZN Stock Holding History

Covenant Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.94M	Sell	41,874 -1,981	-5%	-$373K	1.34%	22
2026 Q1	$8.65M	Buy	43,855 +41,788	+2,022%	+$8.06M	1.3%	22
2025 Q4	$380K	Hold	2,067	–	–	0.05%	138
2025 Q3	$317K	Sell	2,067 -50	-2%	-$7.57K	0.04%	136
2025 Q2	$296K	Hold	2,117	–	–	0.04%	131
2025 Q1	$311K	Sell	2,117 -56	-3%	-$8.1K	0.07%	136
2024 Q4	$285K	Sell	2,173 -356	-14%	-$49.8K	0.04%	148
2024 Q3	$394K	Sell	2,529 -13	-0.5%	-$2.1K	0.06%	132
2024 Q2	$396K	Sell	2,542 -106	-4%	-$16K	0.06%	126
2024 Q1	$359K	Buy	2,648 +196	+8%	+$26K	0.06%	117
2023 Q4	$330K	Buy	2,452 +198	+9%	+$25.7K	0.06%	131
2023 Q3	$305K	Hold	2,254	–	–	0.08%	131
2023 Q2	$323K	Hold	2,254	–	–	0.08%	132
2023 Q1	$313K	Hold	2,254	–	–	0.07%	139
2022 Q4	$306K	Hold	2,254	–	–	0.07%	144
2022 Q3	$247K	Hold	2,254	–	–	0.07%	140
2022 Q2	$298K	Hold	2,254	–	–	0.09%	134
2022 Q1	$299K	Hold	2,254	–	–	0.08%	124
2021 Q4	$263K	Hold	2,254	–	–	0.07%	126
2021 Q3	$271K	Buy	+2,254	New	+$262K	0.08%	121

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Covenant Asset Management's AZN Position: Q2 2026 in Review

Covenant Asset Management reduced its AstraZeneca (AZN) stake by 4.5% in Q2 2026, selling an estimated $373K and leaving 41,874 shares worth $7.94M. The position accounts for 1.34% of the portfolio, ranked #22.

Covenant Asset Management first reported a position in AZN in Q3 2021 and has held it in 20 quarters since. The position peaked at $8.65M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Covenant Asset Management held 41,874 shares of AstraZeneca worth $7.94M as of Q2 2026.
Covenant Asset Management sold 1,981 AstraZeneca shares in Q2 2026, an estimated $373K.
AstraZeneca made up 1.34% of Covenant Asset Management's portfolio in Q2 2026, its #22 holding.
Covenant Asset Management first reported a position in AstraZeneca in Q3 2021 and has held it in 20 quarters since.
Covenant Asset Management's AstraZeneca position peaked at $8.65M in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Covenant Asset Management's 13F filing for Q2 2026, filed 20 Jul 2026.